Growth Metrics

Biogen (BIIB) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to -$48.9 million.

  • Biogen's Net Income towards Common Stockholders fell 11833.52% to -$48.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year decrease of 2078.79%. This contributed to the annual value of $1.3 billion for FY2025, which is 2078.79% down from last year.
  • Per Biogen's latest filing, its Net Income towards Common Stockholders stood at -$48.9 million for Q4 2025, which was down 11833.52% from $466.5 million recorded in Q3 2025.
  • In the past 5 years, Biogen's Net Income towards Common Stockholders registered a high of $1.1 billion during Q3 2022, and its lowest value of -$134.8 million during Q3 2021.
  • For the 5-year period, Biogen's Net Income towards Common Stockholders averaged around $392.4 million, with its median value being $395.3 million (2023).
  • As far as peak fluctuations go, Biogen's Net Income towards Common Stockholders plummeted by 12874.51% in 2021, and later surged by 94836.8% in 2022.
  • Quarter analysis of 5 years shows Biogen's Net Income towards Common Stockholders stood at -$101.7 million in 2021, then skyrocketed by 649.66% to $559.0 million in 2022, then plummeted by 55.47% to $248.9 million in 2023, then increased by 7.15% to $266.7 million in 2024, then crashed by 118.34% to -$48.9 million in 2025.
  • Its last three reported values are -$48.9 million in Q4 2025, $466.5 million for Q3 2025, and $634.8 million during Q2 2025.